EnteroBiotix Ltd.

European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome Innovation for Health (EMIH) association today announced an agreement between the Microbiome Therapeutics Innovation Group (MTIG) and EMIH for a collaboration to advance microbiome drug development, explore synergies between international regulators, and convene cross-continental meetings to incorporate the perspectives of a wide-range of drug developers. This new collaboration will incorporate diverse perspectives with the goal of further accelerating microbiome therapeutic product development to expand availability of life-changing and life-saving regulatory approved microbiome therapies to patients. A main priority of the agreement is to harmonize regulatory frameworks from multiple regions to create a more cohesive approach in seeking the necessary policy and regulatory solutions for the issues faced by MT drug developers. “MTIG’s founding principal is to accelerate patients’ access to innovative microbiome therapeutics through our communal efforts,” said Dr. Nikole Kimes, Chairman of MTIG and CEO of Siolta Therapeutics. “The EMIH represents innovative microbiome companies aligned with this core mission, and we look forward to sharing insights with one another to amplify our collective voice and transform the lives of patients on both sides of the Atlantic.” Hervé Affagard, President of EMIH and CEO and co-founder of MaaT Pharma, stated "As leading associations in the microbiome field, we understand that our strength lies in collaboration. By joining forces with MTIG, we will accelerate the development and delivery of microbiome therapies, ensuring that groundbreaking treatments reach those who need them most, swiftly and safely. This partnership embodies our shared commitment to harmonizing regulatory frameworks, and we look forward to working closely with MTIG." EMIH and its members are dedicated to advancing knowledge and fostering the development of bioproductions, diagnostics, and medical devices based on the microbiome for human health. The organization is committed to ensuring equitable access to these innovations by adhering to regulatory frameworks that uphold the highest quality standards, while maintaining an economic balance to support ongoing therapeutic innovation. All pharmaceutical and biotechnology companies seeking regulatory approvals in Europe for microbiome bioproductions, diagnostics, and medical devices are eligible for membership consideration in EMIH. If you are interested in learning more, please contact EMIH here. About The Microbiome Therapeutics Innovation Group The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients. Today, MTIG is comprised of eleven microbiome therapeutics companies: BiomeSense, Biose Industrie, Freya Biosciences, MaaT Pharma, Microba Life Sciences, Rebiotix Inc., a Ferring Company, Seres Therapeutics, Siolta Therapeutics, and Vedanta Biosciences. For more information, visit www.microbiometig.org About European Microbiome Innovation for Health The European Microbiome Innovation for Health (EMIH) is an independent coalition within the European Union, the United Kingdom, and Switzerland, currently comprising 20+ major players from the public and private sectors. From the laboratory to the patient’s bedside, EMIH covers the entire value chain of the microbiome industry. Its goal is to position Europe as a global leader in the development, production, and commercialization of microbiome-based therapeutic innovations. EMIH members include Bioaster, Biocodex, BioGaia, Biofortis, Biose Industrie, Eligo Bioscience, GMT Science, INRAe, Lallemand Health Solutions, Life Avocats, Enosis Santé, EnteroBiotix, Pelican Health, MaaT Pharma, mbiomics, Microbiotica, Microbiome Foundation, MRM Health, Nexbiome, Novobiome, Seventure Partners and SwipeBiome. For more information, please visit www.europeanmicrobiome.org Contact for European Microbiome Innovation for Health Email: p.richaud@europeanmicrobiome.org Attachment EMIH MTIG PR Final_240923

Serial entrepreneur has created, built and sold three CDMOs GAINESVILLE, Fla., May 21, 2024 (GLOBE NEWSWIRE) -- Kincell Bio, LLC (“Kincell”), a technology-forward contract development and manufacturing organization (CDMO) focused on cell therapies, today announced the appointment of Mark R. Bamforth as the Company’s new Board Chairman. This strategic appointment further strengthens Kincell’s position as the Company continues to expand its capacity to provide high-quality support for the cell therapy market. Mr. Bamforth will replace the current Board Chairman, Shailesh Maingi, who will remain on the Board. “In advanced biopharmaceutical manufacturing, Mark has a demonstrated ability to scale best-in-class CDMOs with high performing teams that have been market leaders in the cell and gene therapy, microbiome and monoclonal antibody sectors,” said Mr. Maingi. “As he takes on the role of Board Chairman at Kincell, his wealth of experience and strategic vision plus his commitment to scientific excellence, has the potential to propel the Company to new heights and to deliver cell therapies to clients and their patients.” A serial entrepreneur with decades of experience building value in biotech, Mr. Bamforth has founded, built and sold three CDMOs. He currently invests in and mentors U.S.- and Scottish-based life science entrepreneurs in addition to serving as a general partner in an antimicrobial resistance fund. In May 2019, Mr. Bamforth founded Arranta Bio, an advanced therapeutics CDMO focused on the microbiome, plasmid and mRNA vaccines, which was sold to Recipharm in April 2022. Prior, he founded Brammer Bio, a best-in-class viral vector CDMO for cell and gene therapies that supported leading innovators. Brammer’s team grew six-fold, reaching over 600 employees at the time of its acquisition by Thermo Fisher Scientific in April 2019. In 2010, Mr. Bamforth founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team with a commercial supply agreement with Janssen. The Company tripled through organic growth and merged with Laureate Biopharma, before being sold to DPx Holdings (Patheon) in 2014. Mr. Bamforth spent 22 years at Genzyme, with nearly a decade as a corporate officer leading the Company’s 12-site global manufacturing operation and a pharmaceutical CMO unit. He serves on the boards of Continuus Pharma, Pneumagen, Enterobiotix and Entrepreneurial Scotland. Mr. Bamforth has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. “I’m excited to leverage my experience to help guide the leadership team at Kincell as they continue expanding Kincell’s cell engineering footprint in the delivery of transformative healthcare solutions for clients. The Company’s dedication to innovation, process development and manufacturing excellence resonates deeply with me,” said Mr. Bamforth. “Together, we will accelerate the adoption of our clients’ cell therapies, harnessing the power of cutting-edge technology to revolutionize patient care through personalized medicine.” About Kincell Bio Kincell Bio, LLC (“Kincell” or the “Company”) engineers cells into therapies. The Company is a technology-forward contract development and manufacturing organization (CDMO) formed to streamline analytical development, process development, CMC consulting and GMP manufacturing for cellular therapies. With facilities in Gainesville, Fla. to support early clinical supply production and in Research Triangle Park, North Carolina with a phase II/III facility to support late-stage development, Kincell’s focus is on the development and manufacturing of immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs for clients. For more information, visit Media Contact Gina Mangiaracina 6 Degrees Email: gmangiaracina@6degreespr.com

GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will be used to advance EBX’s lead product candidate, EBX-102-02 through a Phase 2 clinical trial in Irritable Bowel Syndrome (‘IBS’) in partnership with the Functional Gut Clinic, as well as to progress its pipeline for other conditions linked to a disrupted gut microbiome, including liver cirrhosis and hepatic encephalopathy (‘HE’). The financing, which comprises £15.7m of new equity and the conversion of £11.6m of loan notes into equity comes from experienced US-based life science investors Thairm Bio and Kineticos Life Sciences, as well as the Scottish National Investment Bank (‘the Bank’). Existing investors including Scottish Enterprise and many of the Company’s private investors also participated. Dr James McIlroy, CEO of EnteroBiotix, said: “This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome. It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market. We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe.” Contacts: EnteroBiotix Dr James McIlroy CEO at EnteroBiotix j.mcilroy@enterobiotix.com Scius Communications Katja Stout +447789435990 katja@sciuscommunications.com Daniel Gooch +447747875479 daniel@sciuscommunications.com Charlotte Street Partners (for Scottish National Investment Bank enquiries) Anna Dickens (07522 558917) or David Gaffney (07854 609998) thebank@charlottestreetpartners.com About Irritable Bowel Syndrome (IBS) IBS is a chronic relapsing functional gastro-intestinal disorder, with patients experiencing a range of symptoms, such as chronic abdominal pain, cramping, bloating and change in bowel movements – which may include constipation, diarrhoea or both. It is estimated that up to one in eight people suffer from IBS type symptoms, and there is approximately an equal split between patients experiencing predominantly constipation (IBS-C) versus diarrhoea (IBS-D). IBS has a very significant healthcare and economic burden. About EnteroBiotix EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics for patients with serious unmet medical needs. The Company is leveraging its product platform to address patient needs through a pipeline of tailored high-diversity products that fortify and restore the microbiome. EnteroBiotix has a strategic partnership with Imperial College London to enable clinical trials in high-unmet need clinical indications and recently announced the initiation of a Phase 2 clinical trial in IBS. The Company has completed patient enrolment in a Phase 2 clinical study in liver cirrhosis. EnteroBiotix has differentiated platform manufacturing technologies and a well-developed analytical toolkit that confers superior product characteristics. The Company operates sophisticated MHRA licensed manufacturing infrastructure, together with its Number 2® brand, which ensures the safety, security, quality, and sufficiency of supply of microbiota obtained from healthy human donors. Established in 2017, EnteroBiotix is headquartered in Glasgow, Scotland, and operates research laboratories and MHRA licensed GMP pharmaceutical manufacturing sites in Glasgow and Aberdeen. The Company has now raised over £47m from investors, including Thairm Bio, Kineticos Life Sciences, the Scottish National Investment Bank and Scottish Enterprise Growth Equity. For more details see and About The Functional Gut Clinic The Functional Gut Clinic (FGC) is the UK’s leading independent provider of gastrointestinal physiology testing and diagnostics. FGC provides both private and NHS services around the UK and are the only independent GI physiology clinic to have IQIPS / UKAS and CQC accreditation. Established in 2013, FGC has an extensive R&D and Clinical trials portfolio helping to design and test future digestive health tests and treatments. For more details see About the Scottish National Investment Bank The Scottish National Investment Bank (The Bank) is Scotland’s first development investment bank, wholly owned by the Scottish Government ministers on behalf of the people of Scotland since its establishment in November 2020. It is a public limited company (PLC), that operates independently from government. The Bank provides patient (long term) debt or equity investments to businesses and projects throughout Scotland to support the development of a fairer, more sustainable economy. As an impact investor, the Bank is focused on delivering both commercial returns and impacts that align with at least one of its three missions: Net zero: Addressing the climate crisis through growing a fair and sustainable economy Innovation: Scaling up innovation and technology for a more competitive and productive economy Place: Transforming communities to make them places where everyone thrives The Scottish Government has committed to capitalising the Bank with £2bn in its first 10 years. Over time as the Bank’s initial investments are repaid, the Bank will reinvest those funds in businesses and projects, creating a perpetual investment fund to support the Scottish economy in the long term. thebank.scot